A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation [PDF]
Haematologica, 2016 Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén +8 more
doaj +3 more sources
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease [PDF]
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +3 more sources
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease [PDF]
Frontiers in Immunology, 2019 Graft vs. host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Damage to the gastrointestinal (GI) tract from acute GVHD is a particularly serious event that can result in ...
Clint Piper +2 more
doaj +3 more sources
Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance [PDF]
Frontiers in Immunology, 2019 Graft-vs.-host disease (GVHD) remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Hongshuang Yu +5 more
doaj +3 more sources
Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease [PDF]
Frontiers in Immunology, 2019 Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders.
Govindarajan Thangavelu, Bruce R. Blazar
doaj +3 more sources
Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions [PDF]
Frontiers in Immunology, 2020 Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease?
Elizabeth Krieger, Amir Ahmed Toor
doaj +3 more sources
Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience [PDF]
Frontiers in Bioengineering and Biotechnology, 2018 The most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who
Maja Česen Mazič +4 more
doaj +3 more sources
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study [PDF]
, 2020 Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids.
López Corral, Lucía +8 more
core +10 more sources
Donor single nucleotide polymorphism in ACAT1 affects the incidence of graft-versus-host disease after bone marrow transplantation [PDF]
, 2020 Acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1) is an enzyme that converts cholesterol to cholesteryl esters. A recent in vivo study reported that inhibiting ACAT1 enzyme activity upregulates the membrane cholesterol levels of T cells, enhancing ...
Okuno, Shingo +12 more
core +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: The lack of standardization of clinical diagnostic criteria, classification and severity scores of chronic graft-versus-host disease led the National Institutes of Health to propose consensus criteria for the purpose of clinical trials ...
Rita de Cássia Barbosa da Silva Tavares +14 more
doaj +1 more source